Quantcast
Last updated on April 24, 2014 at 21:24 EDT

Latest Dasatinib Stories

2008-11-12 12:00:07

CytRx, a biopharmaceutical company, has announced that INNO-406, the company's potent, orally available, rationally designed, dual Bcr-Abl and Lyn-kinase inhibitor, demonstrated clinical responses in patients with chronic myeloid leukemia. INNO-406 is being evaluated for the treatment of patients with chronic myeloid leukemia (CML) and other leukemias that have a certain mutation called the Philadelphia Chromosome (Ph+) and are intolerant of or resistant to imatinib and second line tyrosine...

2008-11-11 09:00:08

CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical company engaged in the development and commercialization of human therapeutics, today announced that INNO-406, CytRx's potent, orally available, rationally designed, dual Bcr-Abl and Lyn-kinase inhibitor, demonstrated clinical responses in patients with Chronic Myeloid Leukemia (CML). INNO-406 is being evaluated for the treatment of patients with CML and other leukemias that have a certain mutation called the Philadelphia Chromosome (Ph+)...

2008-10-30 06:00:44

GPC Biotech has reported preclinical data on RGB-286638, the company's multi-targeted protein kinase inhibitor, that supported the potential utility of RGB-286638 against some hematological malignancies. The data demonstrated that the RGB-286638 small molecule has potent activity against chronic myeloid leukemia (CML) in in vivo models that are resistant to imatinib (Gleevec) and to dasatinib (Sprycel), the current standards of care for treating this form of cancer. Additionally,...

2008-10-27 06:00:23

GPC Biotech AG (Frankfurt Stock Exchange: GPC, NASDAQ: GPCB) today reported that pre-clinical data on RGB-286638, the Company's multi-targeted protein kinase inhibitor, were presented at the 20th EORTC-NCI-AACR Symposium: Molecular Targets and Cancer Therapeutics in Geneva, Switzerland in a poster entitled, "RGB-286638 is a novel multi-targeted protein kinase inhibitor with activity in chronic myelogenous leukemia (CML) models," (Abstract #578). The data presented demonstrate that the...

2008-06-16 12:01:05

Exelixis has reported preliminary Phase I data from an ongoing trial of XL228 in patients with chronic myelogenous leukemia or Philadelphia chromosome-positive acute lymphocytic leukemia who are resistant to or intolerant of the approved BCR-ABL inhibitors imatinib and dasatinib. Approximately 17 subjects have received at least one dose of XL228, of whom 16 had completed cycle 1. The trial is evaluating a treatment cycle consisting of four weekly one-hour IV infusions of XL228 at doses...

2008-06-16 09:01:19

ChemGenex Pharmaceuticals (ASX:CXS) (NASDAQ:CXSP) announced today the presentation of positive preliminary results from a phase 2 study of omacetaxine mepesuccinate (formerly known as Ceflatonin(R)) in chronic myeloid leukemia (CML) patients who have failed therapy with at least two tyrosine kinase inhibitors (TKIs). These data represent the first findings to be presented from this ongoing study, conducted in patients with or without BCR-ABL mutations. The data presented complement the...

2006-06-28 17:19:35

WASHINGTON (Reuters) - A new Bristol-Myers Squibb Co. pill won U.S. approval for fighting two types of leukemia in patients running out of treatment options, the company said on Wednesday. The drug called Sprycel was shown to help some patients with chronic myeloid leukemia (CML) that had stopped responding to Novartis AG's pill Gleevec. Bristol-Myers said it expects to have the drug on the market within days. In addition to CML, the FDA approval covers treatment of adults with...

2006-06-15 05:20:00

By Gene Emery BOSTON -- Two new drugs may help treat some adult cases of leukemia that fail to respond to Novartis AG's Gleevec, two studies showed on Wednesday. One drug, dasatinib, an experimental Bristol-Myers Squibb drug recently endorsed by a Food & Drug Administration advisory panel, could receive full approval by the end of June. Dasatinib helped 68 out of 84 volunteers suffering from a form of chronic myeloid leukemia, or CML, that was resistant to Novartis's Gleevec, according...

2006-06-14 16:17:58

By Gene Emery BOSTON (Reuters) - Two new drugs may help treat some adult cases of leukemia that fail to respond to Novartis AG's Gleevec, two studies showed on Wednesday. One drug, dasatinib, an experimental Bristol-Myers Squibb Co. drug recently endorsed by a Food & Drug Administration advisory panel, could receive full approval by the end of June. Dasatinib helped 68 out of 84 volunteers suffering from a form of chronic myeloid leukemia, or CML, that was resistant to...